Lupin Manufacturing Solutions unveils Oncology block at Vizag

Written By :  Ruchika Sharma
Published On 2025-11-12 08:00 GMT   |   Update On 2025-11-12 08:00 GMT
Advertisement

Mumbai: Lupin Manufacturing Solutions, a wholly owned subsidiary of global pharma major Lupin Limited, has announced the commissioning of its dedicated Oncology Block at its Vizag facility in India.

The new high-containment unit significantly enhances Lupin Manufacturing Solutions’s end-to-end Contract Development and Manufacturing capabilities for High Potent Active Pharmaceutical Ingredients.
Spanning 4,270 square meters, the new facility, is equipped with 20 reactors, ranging from 250L to 2000L, with over 20 isolators and advanced containment systems, ensuring exposure levels of ≤0.05 µg/m³. Designed with flexible scale-up capabilities (1–35 kg batch range) and comprehensive environmental controls (≤25°C, ≤45% RH), the facility allows for safe, efficient, and compliant production of oncology APIs that meet global quality standards.
Advertisement
Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, commented, “The inauguration of our Oncology Block in Vizag exemplifies our commitment to advancing oncology research and manufacturing. This state-of-the-art facility enhances our capacity to produce high- quality APIs and develop impactful therapies that benefit patients globally. This marks a major milestone in LMS’s evolution into a dedicated and trusted CDMO partner for oncology innovators. With a focus on containment excellence, scalable solutions tailored to each phase, and scientific rigor, this investment enables our global clients to deliver life-changing oncology treatments to patients more quickly, while upholding the highest safety and compliance standards.”
The new facility integrates the Process Development Laboratory with a dedicated Quality Control laboratory, enabling early-stage route scouting, analytical development, process optimization, and validation—all in one location. Supported by scientists with specialized HPAPI expertise, it guarantees seamless transition from lab-scale synthesis to full-scale commercial manufacturing. The facility features advanced containment infrastructure, with isolator-based operations at every process step, integrated SCADA systems, and a effluent detoxification system that complies with global regulatory standards.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News